Medicine and Dentistry
Non-Hodgkin Lymphoma
90%
Oncology
86%
Doxorubicin
66%
CHOP
56%
Vincristine
56%
Cyclophosphamide
52%
Disease
47%
Prednisone
40%
Diffuse Large B-Cell Lymphoma
38%
Neoplasm
37%
Overall Survival
36%
Follicular Lymphoma
34%
Large-Cell Lymphoma
30%
Radiation Therapy
30%
Hodgkin's Lymphoma
30%
Rituximab
25%
Combination Chemotherapy
24%
B Cell
20%
Gene Expression
20%
Prognostic Factor
19%
Progression Free Survival
19%
T Cell
18%
Large Cell
17%
Tositumomab
17%
Phase II Trials
17%
Clinical Trial
16%
Lymphoma
16%
Bleomycin
15%
Breast Cancer
13%
Gene Expression Profiling
13%
Iodine 131
13%
Morphology
12%
Chemotherapy Regimens
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Methotrexate
11%
Peripheral T-Cell Lymphoma
10%
Histiocytic Lymphoma
9%
Mitomycin
9%
B-Cell Lymphoma
9%
Major Histocompatibility Complex
9%
Adenocarcinoma
9%
Patient with Non-Hodgkins Lymphoma
9%
Lymphoblastic Lymphoma
9%
Biopsy
9%
Molecular Profiling
8%
Mantle Cell Lymphoma
8%
Esorubicin
8%
Monoclonal Antibody Ki 67
8%
Chemosensitizer
8%
Mitoxantrone
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Doxorubicin
83%
Chemotherapy
82%
Cyclophosphamide
69%
Vincristine
68%
Prednisone
55%
Disease
55%
Rituximab
33%
Overall Survival
31%
Methotrexate
31%
Progression Free Survival
30%
Neoplasm
29%
Hodgkin Disease
29%
Remission
28%
Bleomycin
25%
Phase II Trials
22%
Etoposide
22%
Tositumomab
21%
Lymphoma
21%
Large Cell Lymphoma
21%
Clinical Trial
20%
Follicular Lymphoma
20%
Diffuse Large B Cell Lymphoma
15%
Iodine-131
14%
Breast Cancer
13%
Bisantrene
13%
Vindesine
12%
Alisertib
12%
Mitoxantrone
12%
Mantle Cell Lymphoma
11%
Chemotherapy Regimens
11%
Cytarabine
10%
Verapamil
10%
Monoclonal Antibody
10%
Adenocarcinoma
9%
Non Small Cell Lung Cancer
9%
Survival Rate
9%
Drug Resistance
8%
P-Glycoprotein
8%
Lactate Dehydrogenase
8%
Esorubicin
8%
Lymphocytic Lymphoma
8%
Galiximab
8%
Small Cell Lung Cancer
8%
B Cell Lymphoma
8%
Malignant Neoplasm
8%
Recurrence Free Survival
8%
Vinblastine
7%
Cisplatin
7%
Monoclonal Antibody Ki 67
7%
Keyphrases
Southwest Oncology Group
41%
Group Studies
29%
Doxorubicin
21%
Chemotherapy
20%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Lymphoma
19%
High-grade non-Hodgkin Lymphoma
19%
Follicular Lymphoma
18%
Non-Hodgkin Lymphoma
17%
Complete Remission
17%
Malignant Lymphoma
17%
Prednisone
17%
Lymphoma Patients
17%
Cyclophosphamide
16%
Bis-pyrene
12%
MACOP-B
12%
Radiotherapy
11%
Unfavorable Histology
11%
Bleomycin
11%
Initial Treatment
10%
Overall Survival
10%
Hodgkin Disease
10%
Phase II Study
10%
Mantle Cell Lymphoma
9%
Methotrexate
9%
Adriamycin
9%
Phase II Trial
9%
Chemosensitizer
9%
Combination Chemotherapy
9%
Vindesine
8%
Salvage Radiotherapy
8%
Chemotherapy Failure
8%
VP16
8%
High Dose
8%
Hodgkin Lymphoma
8%
Large Cell Undifferentiated Carcinoma
8%
Mitoxantrone
8%
T Cells
8%
Complete Response
8%
Progression-free Survival
7%
Etoposide
7%
Cyclin D1 (CCND1)
7%
Involved Field Radiotherapy
7%
Partial Response
7%
Rituximab
6%
Cooperative Group
6%
Median Survival
6%
CHOP Chemotherapy
6%
Subclassification
6%
Chemotherapy Alone
6%